AR119715A1 - Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona - Google Patents

Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona

Info

Publication number
AR119715A1
AR119715A1 ARP200101015A ARP200101015A AR119715A1 AR 119715 A1 AR119715 A1 AR 119715A1 AR P200101015 A ARP200101015 A AR P200101015A AR P200101015 A ARP200101015 A AR P200101015A AR 119715 A1 AR119715 A1 AR 119715A1
Authority
AR
Argentina
Prior art keywords
dioxopiperidin
isoindolin
hodgkin
dione
lymphoma
Prior art date
Application number
ARP200101015A
Other languages
English (en)
Spanish (es)
Inventor
Michael Pourdehnad
Rama Krishna Narla
Antonia Lopez-Girona
Tonia J Buchholz
Anton Maria Soraya Carrancio
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR119715A1 publication Critical patent/AR119715A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP200101015A 2019-04-12 2020-04-08 Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona AR119715A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962833432P 2019-04-12 2019-04-12

Publications (1)

Publication Number Publication Date
AR119715A1 true AR119715A1 (es) 2022-01-05

Family

ID=70465546

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101015A AR119715A1 (es) 2019-04-12 2020-04-08 Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona

Country Status (27)

Country Link
US (3) US11390617B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952880B1 (cg-RX-API-DMAC7.html)
JP (1) JP7562557B2 (cg-RX-API-DMAC7.html)
KR (1) KR102944213B1 (cg-RX-API-DMAC7.html)
CN (1) CN114144182B (cg-RX-API-DMAC7.html)
AR (1) AR119715A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020270917B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020372A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132538A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002651A1 (cg-RX-API-DMAC7.html)
DK (1) DK3952880T3 (cg-RX-API-DMAC7.html)
ES (1) ES3061998T3 (cg-RX-API-DMAC7.html)
FI (1) FI3952880T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251668T1 (cg-RX-API-DMAC7.html)
IL (1) IL287145A (cg-RX-API-DMAC7.html)
LT (1) LT3952880T (cg-RX-API-DMAC7.html)
MA (1) MA55608A (cg-RX-API-DMAC7.html)
MX (1) MX428518B (cg-RX-API-DMAC7.html)
PL (1) PL3952880T3 (cg-RX-API-DMAC7.html)
PT (1) PT3952880T (cg-RX-API-DMAC7.html)
RS (1) RS67593B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111232RA (cg-RX-API-DMAC7.html)
SI (1) SI3952880T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600013T1 (cg-RX-API-DMAC7.html)
TW (1) TWI853014B (cg-RX-API-DMAC7.html)
WO (1) WO2020210418A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107668B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
AU2020369497C1 (en) * 2019-10-21 2026-05-07 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
IL292375A (en) 2019-10-21 2022-06-01 Celgene Corp Solid forms include (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)metyl)benzyl)amino)isoindoline-1 3- Discussion and salts from them, and preparations that include the same and their use
AU2020372333B2 (en) * 2019-10-21 2026-08-06 Celgene Corporation Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
SMT202600194T1 (it) * 2019-10-21 2026-05-12 Celgene Corp Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica
HRP20231487T1 (hr) 2019-10-21 2024-03-01 Celgene Corporation Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona
CN114885602A (zh) * 2019-10-21 2022-08-09 新基公司 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮的药物组合物及其使用方法
IL307257A (en) * 2021-03-29 2023-11-01 Juno Therapeutics Inc A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
US20240207281A1 (en) * 2021-04-21 2024-06-27 Celgene Corporation Methods of treating b-cell lymphoma using combination therapy
CN117241802A (zh) * 2021-04-21 2023-12-15 新基公司 使用2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮治疗非霍奇金淋巴瘤的方法
AU2022300184A1 (en) 2021-06-21 2023-11-16 Celgene Corporation Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione
WO2026099206A1 (en) 2024-11-05 2026-05-15 Celgene Corporation Therapy for the treatment of non-hodgkin lymphoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430669C (en) 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
US8648096B2 (en) * 2006-09-15 2014-02-11 Celgene Corporation N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
EP3351240B1 (en) 2009-05-19 2019-04-10 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
SG183257A1 (en) * 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012177678A2 (en) * 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
UA116544C2 (uk) * 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
US20150297579A1 (en) 2012-11-05 2015-10-22 Celgene Corporation Treatment of cancer with pomalidomide in a renally impaired subject
EP2981262A1 (en) * 2013-04-02 2016-02-10 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
NZ731789A (en) * 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
CN118344338A (zh) * 2018-04-23 2024-07-16 细胞基因公司 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途

Also Published As

Publication number Publication date
RS67593B1 (sr) 2026-01-30
EP3952880A1 (en) 2022-02-16
IL287145A (en) 2021-12-01
SMT202600013T1 (it) 2026-03-09
US11390617B2 (en) 2022-07-19
PL3952880T3 (pl) 2026-05-18
MX428518B (es) 2025-11-13
BR112021020372A2 (pt) 2021-12-07
JP2022527398A (ja) 2022-06-01
US20200325129A1 (en) 2020-10-15
AU2020270917A1 (en) 2021-11-04
TWI853014B (zh) 2024-08-21
DK3952880T3 (da) 2026-01-26
WO2020210418A1 (en) 2020-10-15
EP3952880B1 (en) 2025-12-10
US20240400548A1 (en) 2024-12-05
ES3061998T3 (en) 2026-04-08
HRP20251668T1 (hr) 2026-02-27
US20220324855A1 (en) 2022-10-13
KR20210151895A (ko) 2021-12-14
ZA202107668B (en) 2025-01-29
MX2021012507A (es) 2022-01-24
LT3952880T (lt) 2026-01-26
MA55608A (fr) 2022-02-16
US12103923B2 (en) 2024-10-01
SI3952880T1 (sl) 2026-02-27
JP7562557B2 (ja) 2024-10-07
FI3952880T3 (fi) 2026-02-05
CA3132538A1 (en) 2020-10-15
AU2020270917B2 (en) 2025-08-28
TW202103705A (zh) 2021-02-01
KR102944213B1 (ko) 2026-03-26
CN114144182A (zh) 2022-03-04
CL2021002651A1 (es) 2022-04-29
SG11202111232RA (en) 2021-11-29
PT3952880T (pt) 2026-02-17
CN114144182B (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
CL2021002651A1 (es) Métodos de tratamiento del linfoma no hodgkin usando 2- (2,6-dioxopiperidin-3-yl) -4 - ((2-fluoro-4 - ((3-morfolinoazetidin-1-yl) metil) bencil) amino) isoindolina- 1,3-diona
ZA202400786B (en) Glp-1 receptor agonist and composition and use thereof
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
PE20071184A1 (es) Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo
MX2021007925A (es) Inhibidores irreversibles de la interaccion menina-mll.
JOP20190142A1 (ar) مركبات 7-فينيل إيثيل أمينو-4h-بيريميدو[4، 5-d] وبيريدو[4، 3-d]-1، 3-أكسازين-2-ون كمثبطات idh1 وidh2 الطافر
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
MX2020013116A (es) Sales y cristales novedosos.
SG11201811697SA (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
UY33397A (es) Forma sólida de un naftaleno carboxamida
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
ZA202204446B (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
EP4691560A3 (en) Vmat2 inhibitor compounds, compositions, and methods relating thereto
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
EA201891578A1 (ru) Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил-2,2-дифторацетамида
BR112022007417A2 (pt) Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona
CO2018006929A2 (es) "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"
AR053984A1 (es) Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas
UA101961C2 (xx) Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида
MX2018013729A (es) Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma.
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical